Pavlos Msaouel, MD, PhD

Dr. Pavlos Msaouel notes that platinum-based chemotherapy remains a stalwart treatment but immunotherapies lead to less-than-optimal results.

Learn the warning signs of renal medullary carcinoma—sickle cell trait, right-sided mass—and why INI1 testing changes therapy and survival.

Immunohistochemistry is the gold standard for diagnosing renal medullary carcinoma, as genetic sequencing often misses key SMARCB1 alterations.

As one of the rare subtypes of renal cell carcinoma, renal medullary carcinoma presents with some distinct signs: male, Black, between 12 and 45 years of age, sickle cell trait, and a mass in the right kidney.

Pavlos Msaouel, MD, PhD, discusses how the treatments and outcomes differ between patients with the rarer disease of renal medullary carcinoma than the more common renal cell carcinoma.